Online inquiry

IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15707MR)

This product GTTS-WQ15707MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15707MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4388MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ1059MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ6676MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ11359MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ5121MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ9707MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ4751MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BPS-804
GTTS-WQ2060MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AH-PD1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW